Jill Ohar to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Jill Ohar has written about Randomized Controlled Trials as Topic.
Connection Strength
0.414
-
Ohar JA, Sharma S, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sanjar S. Efficacy of Indacaterol/Glycopyrrolate in Patients with COPD by Airway Reversibility at Baseline: A Pooled Analysis of the FLIGHT1 and FLIGHT2 12-Week Studies. COPD. 2019 04; 16(2):133-139.
Score: 0.140
-
Ohar J, Tosiello R, Goodin T, Sanjar S. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4. Int J Chron Obstruct Pulmon Dis. 2019; 14:27-37.
Score: 0.135
-
Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs. 2012 Feb 12; 72(3):301-8.
Score: 0.084
-
Barnes CN, Mahler DA, Ohar JA, Lombardi DA, Crater GD. Peak Inspiratory Flows: Defining Repeatability Limits and a Predictive Equation for Different Inhalers. Chest. 2020 10; 158(4):1413-1419.
Score: 0.037
-
Cazzola M, Hanania NA, Jones PW, Mahler DA, Make B, Ohar J, Rennard S. It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
Score: 0.016